Survival and desferrioxamine in thalassaemia major.
A small randomised trial and observation of all patients homozygous for beta-thalassaemia in Britain born in or before 1963 indicated that those patients who had received average weekly doses of more than 4 g of desferrioxamine over the previous few years were less likely to die in the near future than were patients of similar ages who had received less, or no, desferrioxamine.
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003676:Deferoxamine / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008017:Life Expectancy; D011897:Random Allocation; D013789:Thalassemia / Q000188:drug therapy* / Q000401:mortality
D003676:Deferoxamine